Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 1

Interventions

Specimen Handling 116pembrolizumab 112Magnetic Resonance Spectroscopy 99Carboplatin 83Cyclophosphamide 70Biopsy 63Cisplatin 59Paclitaxel 56Bevacizumab 56Gemcitabine 48Nivolumab 45fludarabine 39Dexamethasone 37atezolizumab 36Rituximab 36Pemetrexed 36Fluorouracil 36Docetaxel 35Leucovorin 32Doxorubicin 31venetoclax 30Radiotherapy 30Oxaliplatin 29Capecitabine 29Temozolomide 27Prednisone 26Cetuximab 26130-nm albumin-bound paclitaxel 25Standard of Care 24Letrozole 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × daromun × 30 days × Clear all
NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Philogen S.p.A.

Phase 2 Recruiting
180 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡